ABBV AbbVie Inc.
Company Analysis
Latest News
AbbVie Lung Cancer Drug Hits 90% Response Rate in Early Trial
AbbVie presented new clinical data from its lung cancer research programs at the 2026 World Conference on Lung Cancer (WCLC). The company is developing a...
AbbVie's Obesity Drug Partner Gubra Reports Positive Phase 1 Data for Amylin Analog
Gubra A/S, a partner of AbbVie, announced encouraging topline data for ABBV-295. ABBV-295 is an amylin analog developed for obesity. The data comes from a...
🟢 AbbVie is trading 3.04% up today as healthcare stocks rally
AbbVie is trading 3.04% up at $266.79 as healthcare stocks rally, investors rotate toward defensive growth, and sector earnings outlooks improve. - No fresh...
🟢 AbbVie is trading 3.07% up today as healthcare stocks rally
AbbVie is trading 3.07% up at $258.02, with the move appearing primarily tied to healthcare-led sector rotation, not a new AbbVie-specific announcement. -...
AbbVie Target Raised to $300, Wells Fargo Eyes $6.5 Billion Drug Peak
Wells Fargo raised its price target for AbbVie Inc. to $300 from $295. The firm also reiterated its Overweight rating on the stock. Analysts identified...
AbbVie Upgraded to Outperform by Wolfe Research
Wolfe Research upgraded AbbVie Inc. The firm raised its rating to 'Outperform' from 'Peerperform'. It set a price target of $300. Canada recommended...
AbbVie Advances $10.9B Apogee Deal, Strengthening Immunology Pipeline After Vote
Apogee Therapeutics shareholders approved AbbVie’s planned acquisition of the company for approximately $10.9 billion. This vote clears a major hurdle for the...
AbbVie Announces $10.0 Billion Senior Notes Offering to Fund Apogee Acquisition
AbbVie Inc. has entered into an underwriting agreement to issue and sell nine series of senior notes with an aggregate principal amount of $10.0 billion. The...
AbbVie Beats on Revenue, Then Cuts Its Own Profit Forecast — Can a $10.9 Billion Bet on Eczema Justify Six Years of Thinner Earnings?
Shares slid 3.8% to $247.52 this morning after AbbVie delivered a strong Q2 beat but simultaneously trimmed its full-year profit outlook to absorb the cost of...
🔴 AbbVie is trading 3.8% down today after trimming profit outlook despite strong Q2 results
AbbVie is trading 3.8% down at $247.52 after trimming its 2026 profit outlook to fund a $10.9 billion acquisition of Apogee and accelerate pipeline...
AbbVie's second quarter revenue grew 10.2% to $16.99B, beating estimates on strong immunology franchise performance.
AbbVie reported second quarter net revenues of $16.99 billion, an increase of 10.2% year-over-year, while adjusted diluted EPS was $3.65, a 22.9% increase from...
🔴 AbbVie is trading 3.1% down today as investors position ahead of Q2 earnings
AbbVie is trading 3.1% down at $255.21 as investors position ahead of its Q2 2026 earnings report scheduled for July 31, 2026. • The price action suggests...
AbbVie Inc. Q2 2026 Earnings Preview: What Analysts Expect on July 31, 2026
AbbVie's Q2 2026 consensus revenue is $16.81 billion and EPS is $3.66, with shares recently trading at $265.52 against an average analyst target of...
AbbVie secures EU approval for Rinvoq, first systemic treatment for vitiligo
The European Commission approved AbbVie’s Rinvoq (upadacitinib) to treat non-segmental vitiligo in adults and adolescents aged 12 and older. This decision...
AbbVie’s RINVOQ Wins EU Approval, First JAK Inhibitor for Hair Loss
The European Commission approved AbbVie’s RINVOQ (upadacitinib) to treat severe alopecia areata in adults and adolescents aged 12 and older. This decision...
🟢 AbbVie is trading 3.1% up today on pre-earnings positioning and immunology pipeline optimism
AbbVie is trading 3.1% up at $264.85 as investors position ahead of its July 31, 2026, Q2 earnings release. • Recent analyst price-target increases and...
AbbVie and Genmab Miss Survival Goal in Phase 3 Lymphoma Trial
AbbVie and development partner Genmab announced that epcoritamab failed its primary goal in the Phase 3 EPCORE DLBCL-1 trial. The study evaluated the drug in...
AbbVie wins EU approval for Boey, a rapid-onset frown line treatment
AbbVie’s Allergan Aesthetics received European Commission approval for Boey (trenibotulinumtoxinE). The authorization covers all 30 European Economic Area...
🟢 AbbVie is trading 3.15% up today on broad healthcare sector strength
AbbVie is trading at $251.79 (+3.15%) in mid-morning trading, driven by broad strength across the healthcare sector. • The Health Care Select Sector SPDR Fund...
AbbVie lowers second quarter and full-year 2026 EPS guidance by $0.17 due to a $291 million R&D expense.
AbbVie updated its financial guidance for the second quarter and full-year 2026, lowering its adjusted EPS forecast to incorporate a significant research and...